Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Smad family member proteins are a group of structurally related intracellular proteins that serve as the main signal transducers for receptors of the transforming growth factor-beta (TGF-beta) superfamily. They play a central role in transmitting signals from TGF-beta ligands at the cell surface to the nucleus where they regulate gene expression. The family is divided into three functional classes: • Receptor-regulated Smads (R-Smads): These include SMAD1, 2, 3, 5 and 8. They are directly phosphorylated by type I TGF-beta receptors upon ligand binding. • Common-mediator Smad (Co-Smad): This is primarily represented by SMAD4 which forms complexes with R-Smads to facilitate nuclear translocation and DNA binding. • Inhibitory Smads (I-Smads): These include SMAD6 and SMAD7 which act as antagonists to TGF-beta signaling by preventing activation or promoting degradation of receptor complexes. Structurally, all canonical members have two conserved domains—MH1 at the N-terminal for DNA binding and MH2 at the C-terminal for protein-protein interactions—connected by a regulatory linker region. Upon activation through phosphorylation events mediated by upstream kinases such as CDK8/9 or GSK3 in response to extracellular signals like TGF-beta or bone morphogenetic proteins (BMPs), R-Smads form trimers with Co-Smad(s) that accumulate in the nucleus to regulate target gene transcription. Smad proteins are essential regulators of diverse biological processes including embryonic development patterning, cell growth control, apoptosis induction/suppression depending on context, tissue homeostasis maintenance and immune responses. Dysregulation or mutation in specific members has been implicated in various diseases such as cancer progression/metastasis and fibrotic disorders due to aberrant signaling pathway activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Smad family member protein (SMAD).